Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results

David J. Conti, Roman Petrov, Ossama Elbalhoul, Michael Gallichio

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


At the Albany Medical Center, we have a long-term experience, mean follow-up of 75 months, in 50 renal transplant recipients treated with maintenance sirolimus, prednisone and a calcineurin-inhibitor sparing immunosuppressive regimen. One-year patient and graft survival was 98% and six-year patient and graft survival was 82% and 72% respectively. The rate of early acute rejection (< 3 months) was only 10%. Furthermore, no late (> 3 months) acute rejection episodes developed despite calcineurin-inhibitor dose minimization. In addition, recipient mean serum creatinine remained stable at 1.6 mg/dl throughout the 6-year follow-up period. Sirolimus is an effective maintenance immunosuppressive agent that safely allows for a reduction in calcineurin-inhibitor dosing.

Original languageEnglish (US)
Pages (from-to)12-13
Number of pages2
JournalTransplant Immunology
Issue number1-2
StatePublished - Nov 2008
Externally publishedYes


  • Calcineurin-inhibitor sparing
  • Long-term results
  • Sirolimus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation


Dive into the research topics of 'Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results'. Together they form a unique fingerprint.

Cite this